Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma Meeting the Primary Endpoint

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Interim Analysis of the Phase III Clinical Trial of iza-bren (EGFR×HER3 Bispecific ADC) for the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma Meeting the Primary Endpoint

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis